Abstract
Bir lökotrien reseptör antagonisti olan montelukast çocukluk çağı astım tedavisinde sıklıkla kullanılan bir ajandır. İlacın çeşitli nöropsikiyatrik yan etkileri giderek artan bir şekilde rapor edilmektedir. Bu olgu sunumunda, daha öncesinde genetik yatkınlığı ve psikolojik sorunu olmayan, montelukast kullanımı sonrası depresyon ve intihar düşüncesi/davranışı sergileyen, ilaç kesilmesi ile yakınmaları tamamen kaybolan bir olguyu rapor ediyoruz.
References
- Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008;31: 143-78.
- Full Drug Prescribing information, MERCK & CO., INC. available at www.singulair.com/montelukast_sodium/hcp/asthma/prescribing- information.jsp accessed 17/09/10.
- Philip G, Hustad CM, Malice MP, Noonan G, Ezekowitz A, Reiss TF, et al. Analysis of behavior-related adverse experiences in clinical trials of montelukast. J Allergy Clin Immunol 2009;124:699-706.
- Leff JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. Engl J Med 1998;339:147-52.
- Türkiye Çocuk Hast Derg/Turkish J Pediatr Dis / 2014; 4: 212-214
- Wallerstedt SM, Brunlof G, Sundstrom A, Eriksson AL. Montelukast and psychiatric disorders in children. Pharmacoepidemiol Drug Saf 2009;18:858-64.
- Philip G, Hustad C, Noonan G, Malice MP, Ezekowitz A, Reiss TF, et al. Reports of suicidality in clinical trials of montelukast. J Allergy Clin Immunol 2009;124:691-6.
- Skillman KL, Stumpf JL. Montelukast-induced anxiety in two pediatric patients. Pharmacotherapy 2011;31:524
- Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
Abstract
Montelukast, a leukotriene receptor antagonistis a commonly prescribed medication in management of asthma in children. It has been associated with increased risk of various neuropsychiatric events. Here, we report a young boy who presents a number of unusual neuropsychiatric events (suicide behavior) after montelukast usage. The complete resolution of the symptoms was seen upon the withdrawal of the medication
References
- Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008;31: 143-78.
- Full Drug Prescribing information, MERCK & CO., INC. available at www.singulair.com/montelukast_sodium/hcp/asthma/prescribing- information.jsp accessed 17/09/10.
- Philip G, Hustad CM, Malice MP, Noonan G, Ezekowitz A, Reiss TF, et al. Analysis of behavior-related adverse experiences in clinical trials of montelukast. J Allergy Clin Immunol 2009;124:699-706.
- Leff JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. Engl J Med 1998;339:147-52.
- Türkiye Çocuk Hast Derg/Turkish J Pediatr Dis / 2014; 4: 212-214
- Wallerstedt SM, Brunlof G, Sundstrom A, Eriksson AL. Montelukast and psychiatric disorders in children. Pharmacoepidemiol Drug Saf 2009;18:858-64.
- Philip G, Hustad C, Noonan G, Malice MP, Ezekowitz A, Reiss TF, et al. Reports of suicidality in clinical trials of montelukast. J Allergy Clin Immunol 2009;124:691-6.
- Skillman KL, Stumpf JL. Montelukast-induced anxiety in two pediatric patients. Pharmacotherapy 2011;31:524
- Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
Details
| Other ID | JA84ZP43BJ |
|---|---|
| Journal Section | Case Report |
| Authors | |
| Publication Date | April 1, 2014 |
| Submission Date | April 1, 2014 |
| Published in Issue | Year 2014 Volume: 8 Issue: 4 |
The publication language of Turkish Journal of Pediatric Disease is English.
Manuscripts submitted to the Turkish Journal of Pediatric Disease will go through a double-blind peer-review process. Each submission will be reviewed by at least two external, independent peer reviewers who are experts in the field, in order to ensure an unbiased evaluation process. The editorial board will invite an external and independent editor to manage the evaluation processes of manuscripts submitted by editors or by the editorial board members of the journal. The Editor in Chief is the final authority in the decision-making process for all submissions. Articles accepted for publication in the Turkish Journal of Pediatrics are put in the order of publication, with at least 10 original articles in each issue, taking into account the acceptance dates. If the articles sent to the reviewers for evaluation are assessed as a senior for publication by the reviewers, the section editor and the editor considering all aspects (originality, high scientific quality and citation potential), it receives publication priority in addition to the articles assigned for the next issue.
The aim of the Turkish Journal of Pediatrics is to publish high-quality original research articles that will contribute to the international literature in the field of general pediatric health and diseases and its sub-branches. It also publishes editorial opinions, letters to the editor, reviews, case reports, book reviews, comments on previously published articles, meeting and conference proceedings, announcements, and biography. In addition to the field of child health and diseases, the journal also includes articles prepared in fields such as surgery, dentistry, public health, nutrition and dietetics, social services, human genetics, basic sciences, psychology, psychiatry, educational sciences, sociology and nursing, provided that they are related to this field. can be published.